Jacques Lux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacques Lux has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Adam Woodward
Department of Radiology Translational Research in Ultrasound Theranostics (TRUST) Program University of Texas Southwestern Medical Center Dallas TX 75390 USA
6 shared publications- Caroline de Gracia Lux
UT Southwestern Medical Center, Dallas
6 shared publications Robert F. Mattrey
Department of Radiology, Translational Research in Ultrasound Theranostics (TRUST) Program
6 shared publicationsConnor Endsley
Department of Radiology Translational Research in Ultrasound Theranostics (TRUST) Program University of Texas Southwestern Medical Center Dallas TX 75390 USA
5 shared publicationsNazia Hafeez
UT Southwestern Medical Center
5 shared publicationsJulien Santelli
Department of Radiology, Translational Research in Ultrasound Theranostics (TRUST) Program
4 shared publications
Latest Publications
- Open Access
Systemic Nanobubbles Enable Ultrasound-Guided STING Immunotherapy in Breast Cancer
Activation of the STING pathway can induce potent antitumor immunity, but effective delivery of STING agonists to the tumor while limiting systemic exposure remains challenging. We previously developed MUSIC, an ultrasound-guided platform that uses microbubbles (MBs) to deliver the STING agonist 2′3′-cGAMP and locally activate antitumor immunity. However, the vascular confinement of MBs and the need for intratumoral administration limit the potential for systemic tumor targeting. To overcome these limitations, we developed SONATA (Systemic Oncotherapy using Nanobubbles for Acoustically-guided Tumor Activation), which employs nanobubbles (NBs) that are approximately 10-fold smaller than conventional MBs, enabling systemic administration and tumor extravasation. Following NB accumulation within tumors, ultrasound exposure triggers localized cGAMP release, facilitating delivery to targeted CD11b+ antigen-presenting cells (APCs) and STING activation with spatial and temporal control. NBs are composed of the same components as MBs, including phospholipid shells and a perfluorobutane core and are functionalized with anti-CD11b antibodies to target CD11b+ APCs and spermine-modified dextran to stably load cGAMP through nanocomplex formation. Upon ultrasound activation, SONATA induced phosphorylation of STING, TBK1, and IRF3 and increased IFN-β production in bone marrow-derived macrophages. In an orthotopic breast cancer model, intravenously administered SONATA combined with tumor-localized ultrasound significantly inhibited tumor growth compared with controls. Furthermore, SONATA synergized with immune checkpoint blockade prolonged the median survival of tumor-bearing mice. Collectively, these findings establish SONATA as a systemically administered immunotherapy platform that enables ultrasound-guided, spatially controlled STING activation.
Open AccessSystemic Nanobubbles Enable Ultrasound-Guided STING Immunotherapy in Breast Cancer
Activation of the STING pathway can induce potent antitumor immunity, but effective delivery of STING agonists to the tumor while limiting systemic exposure remains challenging. We previously developed MUSIC, an ultrasound-guided platform that uses microbubbles (MBs) to deliver the STING agonist 2′3′-cGAMP and locally activate antitumor immunity. However, the vascular confinement of MBs and the need for intratumoral administration limit the potential for systemic tumor targeting. To overcome these limitations, we developed SONATA (Systemic Oncotherapy using Nanobubbles for Acoustically-guided Tumor Activation), which employs nanobubbles (NBs) that are approximately 10-fold smaller than conventional MBs, enabling systemic administration and tumor extravasation. Following NB accumulation within tumors, ultrasound exposure triggers localized cGAMP release, facilitating delivery to targeted CD11b+ antigen-presenting cells (APCs) and STING activation with spatial and temporal control. NBs are composed of the same components as MBs, including phospholipid shells and a perfluorobutane core and are functionalized with anti-CD11b antibodies to target CD11b+ APCs and spermine-modified dextran to stably load cGAMP through nanocomplex formation. Upon ultrasound activation, SONATA induced phosphorylation of STING, TBK1, and IRF3 and increased IFN-β production in bone marrow-derived macrophages. In an orthotopic breast cancer model, intravenously administered SONATA combined with tumor-localized ultrasound significantly inhibited tumor growth compared with controls. Furthermore, SONATA synergized with immune checkpoint blockade prolonged the median survival of tumor-bearing mice. Collectively, these findings establish SONATA as a systemically administered immunotherapy platform that enables ultrasound-guided, spatially controlled STING activation.
- 30 December 2025
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (1) , e70044
Advances in Peptide‐Based Cancer Vaccines: Materials, Targeting, and Delivery Strategies
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed cancer treatment by achieving durable responses in a subset of patients. However, the effectiveness of ICIs is often limited by factors such as low tumor expression of PD‐L1 and low tumor mutational burden, which contribute to immune evasion in “cold” tumors. Cancer vaccination through the delivery of tumor antigens offers a promising strategy to enhance antigen‐specific immune priming and improve the responses to ICIs. Despite this potential, peptide‐based cancer vaccines face several challenges, including immune tolerance, insufficient antigen delivery and presentation, and the immunosuppressive tumor microenvironment. To overcome these barriers, novel platforms are being developed to codeliver antigens with immunostimulatory agents. In this review, we highlight recent advances in peptide‐based cancer vaccine design, including innovative materials, adjuvants, targeting strategies, and controlled release mechanisms. We also discuss their translation and how these approaches may ultimately expand the benefit of immunotherapy to patients with treatment‐refractory cancers. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Peptide‐Based Structures Biology‐Inspired Nanomaterials > Lipid‐Based Structures
- 30 December 2025
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (1) , e70044
Advances in Peptide‐Based Cancer Vaccines: Materials, Targeting, and Delivery Strategies
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed cancer treatment by achieving durable responses in a subset of patients. However, the effectiveness of ICIs is often limited by factors such as low tumor expression of PD‐L1 and low tumor mutational burden, which contribute to immune evasion in “cold” tumors. Cancer vaccination through the delivery of tumor antigens offers a promising strategy to enhance antigen‐specific immune priming and improve the responses to ICIs. Despite this potential, peptide‐based cancer vaccines face several challenges, including immune tolerance, insufficient antigen delivery and presentation, and the immunosuppressive tumor microenvironment. To overcome these barriers, novel platforms are being developed to codeliver antigens with immunostimulatory agents. In this review, we highlight recent advances in peptide‐based cancer vaccine design, including innovative materials, adjuvants, targeting strategies, and controlled release mechanisms. We also discuss their translation and how these approaches may ultimately expand the benefit of immunotherapy to patients with treatment‐refractory cancers. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Peptide‐Based Structures Biology‐Inspired Nanomaterials > Lipid‐Based Structures
- Open Access
- 14 July 2025
- Published by Wiley in Small Methods
- Vol. 10 (3) , e2500945
An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations
Acute Lymphoblastic Leukemia (ALL) accounts for over 25% of pediatric cancers. It affects lymphoid progenitor cells, leading to overproduction of immature B‐ or T‐cells. ALL cells rely on asparagine for survival. Therefore, the addition of l ‐asparaginase (ASNase), an enzyme that depletes asparagine, to the ALL chemotherapy backbone has dramatically improved treatment outcomes. However, marketed formulations of l ‐ASNase, all derived from bacteria, with or without polyethylene glycol (PEG) modification, cause allergic reactions to the enzyme or to PEG, impacting treatment efficacy. Herein, existing procedures are capitalized on to propose an integrated set of improved methods to evaluate the efficacy of ASNase formulations against B‐cell ALL in mice, comprising the establishment of an ALL murine model not requiring humanization, an amino acid depletion study, and an assessment of antibody production. It is shown that unmodified ASNase results in short‐lived asparagine depletion and a strong immune response. PEG‐ASNase produces longer‐lasting asparagine depletion, reduces ALL cell counts, and minimizes anti‐ASNase immunogenicity but induces an increased immune response to PEG and is not curative without the chemotherapy backbone. With the increasing use of PEG‐modified drugs, these tools offer a framework for assessing pharmacokinetics and immunogenicity of new enzyme‐based therapeutics or nanoparticles.
- 14 July 2025
- Published by Wiley in Small Methods
- Vol. 10 (3) , e2500945
Open AccessAn Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations
Acute Lymphoblastic Leukemia (ALL) accounts for over 25% of pediatric cancers. It affects lymphoid progenitor cells, leading to overproduction of immature B‐ or T‐cells. ALL cells rely on asparagine for survival. Therefore, the addition of l ‐asparaginase (ASNase), an enzyme that depletes asparagine, to the ALL chemotherapy backbone has dramatically improved treatment outcomes. However, marketed formulations of l ‐ASNase, all derived from bacteria, with or without polyethylene glycol (PEG) modification, cause allergic reactions to the enzyme or to PEG, impacting treatment efficacy. Herein, existing procedures are capitalized on to propose an integrated set of improved methods to evaluate the efficacy of ASNase formulations against B‐cell ALL in mice, comprising the establishment of an ALL murine model not requiring humanization, an amino acid depletion study, and an assessment of antibody production. It is shown that unmodified ASNase results in short‐lived asparagine depletion and a strong immune response. PEG‐ASNase produces longer‐lasting asparagine depletion, reduces ALL cell counts, and minimizes anti‐ASNase immunogenicity but induces an increased immune response to PEG and is not curative without the chemotherapy backbone. With the increasing use of PEG‐modified drugs, these tools offer a framework for assessing pharmacokinetics and immunogenicity of new enzyme‐based therapeutics or nanoparticles.
- 11 April 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (5) , 4046-4054
Perfluorohexane Emulsions Induce Macrophage-Stimulating Effects through iNOS Expression
Despite advances in cancer immunotherapy, efficacy has been limited to a subset of patients, highlighting the need for continued development of innovative therapeutic approaches. Perfluorocarbon-filled (PFC) particles, due to unique physicochemical properties, biological stability, and quantifiability as 19F-MRI tracers, have been intensely investigated as in vivo macrophage imaging agents. Despite this, little is known about the effect of PFC particle uptake on macrophage behavior. Here, phospholipid-stabilized perfluorohexane (PFH) nanodroplets (NDs) were used to treat bone-marrow-derived macrophages (BMDMs) in vitro and tumor-implanted mice in vivo. Physiological response was assessed by using biochemistry, flow cytometry, fluorescence imaging, and tumor measurements. The incubation of alternatively-activated (M2) BMDMs with PFH NDs led to a dose- and time-dependent increase of iNOS expression but not that of other common M1 or M2 markers. PFH ND-induced iNOS expression was further enhanced when treated M2 BMDMs were co-cultured with MC38 murine colon carcinoma cells, resulting in more effective tumoral cell apoptosis. Similarly, intratumoral injection of PFH NDs in a murine colon carcinoma model led to increased iNOS expression within the tumors and caused a substantial decrease in tumor size. This size reduction was also unexpectedly accompanied by the formation of peritumoral gas pockets, which, when aspirated, abrogated tumoral effects. Conversely, intratumoral injection of emulsions made with high-boiling-point (BP = 142 °C) perfluorooctyl bromide (PFOB) did not produce gas pockets or inhibit tumor growth. Our data collectively show the immunogenic potential of PFH NDs through iNOS expression and promote the potential development of theranostic PFC-based platforms.
- 11 April 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (5) , 4046-4054
Perfluorohexane Emulsions Induce Macrophage-Stimulating Effects through iNOS Expression
Despite advances in cancer immunotherapy, efficacy has been limited to a subset of patients, highlighting the need for continued development of innovative therapeutic approaches. Perfluorocarbon-filled (PFC) particles, due to unique physicochemical properties, biological stability, and quantifiability as 19F-MRI tracers, have been intensely investigated as in vivo macrophage imaging agents. Despite this, little is known about the effect of PFC particle uptake on macrophage behavior. Here, phospholipid-stabilized perfluorohexane (PFH) nanodroplets (NDs) were used to treat bone-marrow-derived macrophages (BMDMs) in vitro and tumor-implanted mice in vivo. Physiological response was assessed by using biochemistry, flow cytometry, fluorescence imaging, and tumor measurements. The incubation of alternatively-activated (M2) BMDMs with PFH NDs led to a dose- and time-dependent increase of iNOS expression but not that of other common M1 or M2 markers. PFH ND-induced iNOS expression was further enhanced when treated M2 BMDMs were co-cultured with MC38 murine colon carcinoma cells, resulting in more effective tumoral cell apoptosis. Similarly, intratumoral injection of PFH NDs in a murine colon carcinoma model led to increased iNOS expression within the tumors and caused a substantial decrease in tumor size. This size reduction was also unexpectedly accompanied by the formation of peritumoral gas pockets, which, when aspirated, abrogated tumoral effects. Conversely, intratumoral injection of emulsions made with high-boiling-point (BP = 142 °C) perfluorooctyl bromide (PFOB) did not produce gas pockets or inhibit tumor growth. Our data collectively show the immunogenic potential of PFH NDs through iNOS expression and promote the potential development of theranostic PFC-based platforms.
- Open Access
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (22) , e2416596
Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma
Despite the recent successes of immune checkpoint inhibitors (ICIs) in treating advanced melanoma, durable clinical responses still remain limited. To boost immune responses, agents that target immune regulators, such as the Stimulator of Interferon Genes (STING) agonist cyclic GMP‐AMP (cGAMP), are being investigated. However, their clinical translation is impeded by poor serum stability, rapid tissue clearance, and T‐cell death due to off‐target activation. Recently, a novel strategy termed Microbubble‐assisted UltraSound‐guided Immunotherapy of Cancer (MUSIC) has been reported to selectively deliver cGAMP directly into the cytosol of antigen‐presenting cells with spatiotemporal control. The resulting activation of STING and downstream proinflammatory pathways produces antitumor effects in murine models of breast cancer. Herein, this study reports that MUSIC provides curative results in aggressive murine models of melanoma as well. Under ultrasound exposure, MUSIC reduces tumor size, increases overall survival, and synergizes with ICIs to bridge innate and adaptive immunities. The results from this study represent MUSIC's ability to produce potent immune responses in melanoma, thus indicating its potential as an adjuvant for cancers where ICI is the current standard of care.
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (22) , e2416596
Open AccessTargeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma
Despite the recent successes of immune checkpoint inhibitors (ICIs) in treating advanced melanoma, durable clinical responses still remain limited. To boost immune responses, agents that target immune regulators, such as the Stimulator of Interferon Genes (STING) agonist cyclic GMP‐AMP (cGAMP), are being investigated. However, their clinical translation is impeded by poor serum stability, rapid tissue clearance, and T‐cell death due to off‐target activation. Recently, a novel strategy termed Microbubble‐assisted UltraSound‐guided Immunotherapy of Cancer (MUSIC) has been reported to selectively deliver cGAMP directly into the cytosol of antigen‐presenting cells with spatiotemporal control. The resulting activation of STING and downstream proinflammatory pathways produces antitumor effects in murine models of breast cancer. Herein, this study reports that MUSIC provides curative results in aggressive murine models of melanoma as well. Under ultrasound exposure, MUSIC reduces tumor size, increases overall survival, and synergizes with ICIs to bridge innate and adaptive immunities. The results from this study represent MUSIC's ability to produce potent immune responses in melanoma, thus indicating its potential as an adjuvant for cancers where ICI is the current standard of care.
- Open Access
- 1 October 2024
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 156 (4_Suppleme) , A33
Ultrasound-guided activation of the stimulator of interferon genes pathway for cancer immunotherapy
Recent studies have shown that the activation of the innate immune sensor cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS-STING) promotes antigen presentation and T-cell activation, thus transforming cold tumors to immunologically responsive tumors. However, because STING is a cytosolic protein and a key mediator of inflammation, activation of STING needs to be specific to antigen-presenting cells (APCs) in tumor tissues. To address this technical challenge and meet the clinical need, we developed a technology termed MUSIC (Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer) that utilizes gas-filled microbubbles (MBs) conjugated with APC-targeting antibodies, and loaded with the STING activator cGAMP. Our results show that, upon exposure to US, MUSIC produces robust STING activation and type I interferon responses in APCs and more efficiently primes antigen-specific CD4+ and CD8+ T cells in vitro. These immune stimulatory effects of MUSIC directly translated into antitumor responses in vivo, where we showed that the MUSIC was able to generate antitumor effects against syngeneic orthotopic primary (EO771) and metastatic (4T1) murine breast cancer models as well as against two syngeneic murine melanoma models (B16-F10 and D4M). We also confirmed the establishment of systemic immune memory following MUSIC treatments as mice rejected tumor cells upon re-challenge.
- 1 October 2024
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 156 (4_Suppleme) , A33
Open AccessUltrasound-guided activation of the stimulator of interferon genes pathway for cancer immunotherapy
Recent studies have shown that the activation of the innate immune sensor cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS-STING) promotes antigen presentation and T-cell activation, thus transforming cold tumors to immunologically responsive tumors. However, because STING is a cytosolic protein and a key mediator of inflammation, activation of STING needs to be specific to antigen-presenting cells (APCs) in tumor tissues. To address this technical challenge and meet the clinical need, we developed a technology termed MUSIC (Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer) that utilizes gas-filled microbubbles (MBs) conjugated with APC-targeting antibodies, and loaded with the STING activator cGAMP. Our results show that, upon exposure to US, MUSIC produces robust STING activation and type I interferon responses in APCs and more efficiently primes antigen-specific CD4+ and CD8+ T cells in vitro. These immune stimulatory effects of MUSIC directly translated into antitumor responses in vivo, where we showed that the MUSIC was able to generate antitumor effects against syngeneic orthotopic primary (EO771) and metastatic (4T1) murine breast cancer models as well as against two syngeneic murine melanoma models (B16-F10 and D4M). We also confirmed the establishment of systemic immune memory following MUSIC treatments as mice rejected tumor cells upon re-challenge.
- 16 May 2024
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 9 (5) , 2356-2363
Modulating Nonlinear Acoustic Response of Phospholipid-Coated Microbubbles with pH for Ultrasound Imaging
Activatable microbubble contrast agents for contrast-enhanced ultrasound have a potential role for measuring physiologic and pathologic states in deep tissues, including tumor acidosis. In this study, we describe a novel observation of increased harmonic oscillation of phosphatidylcholine microbubbles (PC-MBs) in response to lower ambient pH using a clinical ultrasound scanner. MB echogenicity and nonlinear echoes were monitored at neutral and acidic pH using B-mode and Cadence contrast pulse sequencing (CPS), a harmonic imaging technique at 7.0 and 1.5 MHz. A 3-fold increase in harmonic signal intensity was observed when the pH of PC-MB suspensions was decreased from 7.4 to 5.5 to mimic normal and pathophysiological levels that can be encountered in vivo. This pH-mediated activation is tunable based on the chemical structure and length of phospholipids composing the MB shell. It is also reliant on the presence of phosphate groups, as the use of lipids without phosphate instead of phospholipids completely abrogated this phenomenon. The increased harmonic signal likely is the result of increased MB oscillation caused by a decrease of the interfacial tension induced at a lower pH, altering the lipid conformation. While relative signal changes are interpreted clinically as mostly related to blood flow, pH effects could be significant contributors, particularly when imaging tumors. While our observation can be used clinically, it requires further research to isolate the effect of pH from other variables. These findings could pave the way toward for the development of new smart ultrasound contrast agents that expand the clinical utility of contrast-enhanced ultrasound.
- 16 May 2024
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 9 (5) , 2356-2363
Modulating Nonlinear Acoustic Response of Phospholipid-Coated Microbubbles with pH for Ultrasound Imaging
Activatable microbubble contrast agents for contrast-enhanced ultrasound have a potential role for measuring physiologic and pathologic states in deep tissues, including tumor acidosis. In this study, we describe a novel observation of increased harmonic oscillation of phosphatidylcholine microbubbles (PC-MBs) in response to lower ambient pH using a clinical ultrasound scanner. MB echogenicity and nonlinear echoes were monitored at neutral and acidic pH using B-mode and Cadence contrast pulse sequencing (CPS), a harmonic imaging technique at 7.0 and 1.5 MHz. A 3-fold increase in harmonic signal intensity was observed when the pH of PC-MB suspensions was decreased from 7.4 to 5.5 to mimic normal and pathophysiological levels that can be encountered in vivo. This pH-mediated activation is tunable based on the chemical structure and length of phospholipids composing the MB shell. It is also reliant on the presence of phosphate groups, as the use of lipids without phosphate instead of phospholipids completely abrogated this phenomenon. The increased harmonic signal likely is the result of increased MB oscillation caused by a decrease of the interfacial tension induced at a lower pH, altering the lipid conformation. While relative signal changes are interpreted clinically as mostly related to blood flow, pH effects could be significant contributors, particularly when imaging tumors. While our observation can be used clinically, it requires further research to isolate the effect of pH from other variables. These findings could pave the way toward for the development of new smart ultrasound contrast agents that expand the clinical utility of contrast-enhanced ultrasound.
- Open Access
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Chemical Biology
- Vol. 3, 1386220
Putting the sting back in STING therapy: novel delivery vehicles for improved STING activation
Engaging the immune sensing Stimulator of Interferon Genes (STING) pathway has emerged as a potentially powerful approach to cancer therapy. However, current STING agonists lack stability and specificity, resulting in toxic adverse effects and disappointing patient outcomes. Therefore, novel delivery vehicles are needed to mitigate negative results and improve the efficacy of STING agonists. Here we discuss innovative particle-based strategies and how they have increased the therapeutic results seen with STING agonists. We review ultrasound-responsive vehicles, pH-responsive particles, inorganic particles, carriers for extended release, and particles that act as both STING agonists and/or drug carriers. Further optimization of these strategies can potentially enable the clinical use of STING agonists for cancer therapy.
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Chemical Biology
- Vol. 3, 1386220
Open AccessPutting the sting back in STING therapy: novel delivery vehicles for improved STING activation
Engaging the immune sensing Stimulator of Interferon Genes (STING) pathway has emerged as a potentially powerful approach to cancer therapy. However, current STING agonists lack stability and specificity, resulting in toxic adverse effects and disappointing patient outcomes. Therefore, novel delivery vehicles are needed to mitigate negative results and improve the efficacy of STING agonists. Here we discuss innovative particle-based strategies and how they have increased the therapeutic results seen with STING agonists. We review ultrasound-responsive vehicles, pH-responsive particles, inorganic particles, carriers for extended release, and particles that act as both STING agonists and/or drug carriers. Further optimization of these strategies can potentially enable the clinical use of STING agonists for cancer therapy.
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42413-42423
In Vivo Ultrasound Imaging of Macrophages Using Acoustic Vaporization of Internalized Superheated Nanodroplets
Activating patients' immune cells, either by reengineering them or treating them with bioactive molecules, has been a breakthrough in the field of immunotherapy and has revolutionized treatment, especially against cancer. As immune cells naturally home to tumors or injured tissues, labeling such cells holds promise for non-invasive tracking and biologic manipulation. Our study demonstrates that macrophages loaded with extremely low boiling point perfluorocarbon nanodroplets not only survive ultrasound-induced phase change but also maintain their phagocytic function. Unlike observations made when using higher boiling point perfluorocarbon nanodroplets, our results show that phase change occurs intracellularly at a low mechanical index using a clinical scanner operating within the energy limit set by the Food and Drug Administration (FDA). After nanodroplet-loaded macrophages were given intravenously to nude rats, they were invisible in the liver when imaged at a very low mechanical index using a clinical ultrasound scanner. They became visible when power was increased but still within the FDA limits up to 8 h after administration. The acoustic labeling and in vivo detection of macrophages using a clinical ultrasound scanner represent a paradigm shift in the field of cell tracking and pave the way for potential therapeutic strategies in the clinical setting.
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42413-42423
In Vivo Ultrasound Imaging of Macrophages Using Acoustic Vaporization of Internalized Superheated Nanodroplets
Activating patients' immune cells, either by reengineering them or treating them with bioactive molecules, has been a breakthrough in the field of immunotherapy and has revolutionized treatment, especially against cancer. As immune cells naturally home to tumors or injured tissues, labeling such cells holds promise for non-invasive tracking and biologic manipulation. Our study demonstrates that macrophages loaded with extremely low boiling point perfluorocarbon nanodroplets not only survive ultrasound-induced phase change but also maintain their phagocytic function. Unlike observations made when using higher boiling point perfluorocarbon nanodroplets, our results show that phase change occurs intracellularly at a low mechanical index using a clinical scanner operating within the energy limit set by the Food and Drug Administration (FDA). After nanodroplet-loaded macrophages were given intravenously to nude rats, they were invisible in the liver when imaged at a very low mechanical index using a clinical ultrasound scanner. They became visible when power was increased but still within the FDA limits up to 8 h after administration. The acoustic labeling and in vivo detection of macrophages using a clinical ultrasound scanner represent a paradigm shift in the field of cell tracking and pave the way for potential therapeutic strategies in the clinical setting.
- 22 March 2023
- Published by Springer Nature in Nature Reviews Bioengineering
- Vol. 1 (7) , 499-517
Engineering nanomaterial physical characteristics for cancer immunotherapy
- 22 March 2023
- Published by Springer Nature in Nature Reviews Bioengineering
- Vol. 1 (7) , 499-517
Engineering nanomaterial physical characteristics for cancer immunotherapy